Dimitris Τsokanas

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

F. Kontopidou, S. Papageorgiou, V. Pappa, 2021, Blood Cancer Journal.

Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes

S. Papageorgiou, V. Pappa, E. Hatzimichael, 2020, Hematological oncology.

Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries

F. Kontopidou, S. Papageorgiou, V. Pappa, 2023, Leukemia.